Is advanced age still a risk factor for recurrence of C. difficile infection in the era of new treatments?
Age and Ageing · 2024
DOI: 10.1093/ageing/afae182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Age and Ageing, 2024. Verfasst von Cecilia Suárez-Carantoña und 8 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain. Hauptthemen laut MEDLINE: Clostridium Infections, Recurrence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
Advanced age has been widely identified as a risk factor for recurrent Clostridioides difficile infection (CDI), but most related studies were performed before the introduction of novel therapies. The aim of this study was to compare CDI characteristics and outcomes in patients over and under 80 years old with CDI and their outcomes in the era of new treatments.
Methods
This was a retrospective cohort study of patients diagnosed with CDI from January 2021 to December 2022 in an academic hospital. We compared recurrence and mortality at 12 weeks after the end of treatment. An extension of the Fine and Grey model adjusted for competing events was used to assess the effect of age on recurrence.
Results
Four hundred seventy-six patients were considered to have CDI (320 in patients <80 years and 156 in ≥80 years). CDI in older patients was more frequently healthcare-associated and was more severe. Although the Charlson index was almost identical between populations, comorbidities clearly differed. New treatments (bezlotoxumab, fidaxomicin and faecal microbiota transplantation) were more frequently used in older patients without statistical significance (41.3% vs. 33.4%, P = .053). There were 69 (14.5%) recurrences, with no differences by age group after adjusting for competing events. Mortality was greater in the oldest (35.3%) than in the youngest (13.1%); P < .001.
Conclusions
No differences in CDI recurrence rates were found between age groups. However, there was a high mortality rate in patients ≥80 years old, which emphasises the urgent need to improve the prevention and treatment of CDI in this group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Department, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.
- Faculty of Medicine and Health Sciences, Alcalá University, Madrid, Spain.
- Infectious Diseases Department, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.
- CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
- Biostatistics Department, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.
- CIBER de Epidemiologia y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain.
ORCID-Profile: Cecilia Suárez-Carantoña
Zitieren
APA
Suárez-Carantoña, C., Corbacho-Loarte, M. D., Del Campo Albendea, L., Kamel-Rey, S., Halperin, A. V., Escudero-Sánchez, R., Ponce-Alonso, M., Moreno, S., & Cobo, J. (2024). Is advanced age still a risk factor for recurrence of C. difficile infection in the era of new treatments?. Age and Ageing. https://doi.org/10.1093/ageing/afae182
Vancouver
Suárez-Carantoña C, Corbacho-Loarte MD, Del Campo Albendea L, Kamel-Rey S, Halperin AV, Escudero-Sánchez R, et al. Is advanced age still a risk factor for recurrence of C. difficile infection in the era of new treatments?. Age and Ageing. 2024. doi:10.1093/ageing/afae182
BibTeX
@article{SurezCarantoa2024,
author = {Suárez-Carantoña, Cecilia and Corbacho-Loarte, María Dolores and Del Campo Albendea, Laura and Kamel-Rey, Sara and Halperin, Ana Verónica and Escudero-Sánchez, Rosa and Ponce-Alonso, Manuel and Moreno, Santiago and Cobo, Javier},
title = {Is advanced age still a risk factor for recurrence of C. difficile infection in the era of new treatments?},
journal = {Age and Ageing},
year = {2024},
doi = {10.1093/ageing/afae182}
}
EUVIMED